Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

119M-1

Sigma-Aldrich

CD19 (MRQ-36) Mouse Monoclonal Antibody

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Código UNSPSC:
12352203
NACRES:
NA.41

fonte biológica

mouse

Nível de qualidade

100
500

conjugado

unconjugated

forma do anticorpo

culture supernatant

tipo de produto de anticorpo

primary antibodies

clone

MRQ-36, monoclonal

descrição

For In Vitro Diagnostic Use in Select Regions (See Chart)

Formulário

buffered aqueous solution

reatividade de espécies

human

embalagem

vial of 0.1 mL concentrate (119M-14)
vial of 0.5 mL concentrate (119M-15)
bottle of 1.0 mL predilute (119M-17)
vial of 1.0 mL concentrate (119M-16)
bottle of 7.0 mL predilute (119M-18)

fabricante/nome comercial

Cell Marque®

técnica(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

Isotipo

IgG1κ

controle

tonsil

Condições de expedição

wet ice

temperatura de armazenamento

2-8°C

visualização

membranous

Informações sobre genes

human ... CD19(930)

Descrição geral

CD19 is present in both normal and malignant B-cells and has long been considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, mantle zone cells, and scattered cells in the interfollicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, CD19 is also expressed in immature B-cells; although recent studies have described CD19 loss in a few B-cell neoplasms.

Qualidade


IVD
IVD
IVD
RUO

Ligação

CD19 Positive Control Slides, Product No. 119S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

forma física

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Nota de preparo

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Outras notas

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Informações legais

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

Não está encontrando o produto certo?  

Experimente o nosso Ferramenta de seleção de produtos.

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
0000292400
0000292400

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Y K Onno Teng et al.
Arthritis and rheumatism, 56(12), 3909-3918 (2007-12-01)
Anti-CD20-mediated B cell depletion with rituximab is a new and effective therapy for rheumatoid arthritis (RA). Although B cells in peripheral blood (PB) are consistently depleted in all patients, the clinical effects are more heterogeneous, possibly related to differences in
Oliver M Steinmetz et al.
Transplantation, 84(7), 842-850 (2007-11-07)
Intrarenal B cell clusters are associated with poor clinical outcome in acute interstitial rejection. The incidence of B cell aggregates in vascular rejection and the effect of therapy with the monoclonal CD20 antibody rituximab on intrarenal B cells are currently
S A Greenberg et al.
Neurology, 65(11), 1782-1787 (2005-12-14)
Previous immunohistochemical studies of muscle from patients with inclusion body myositis and polymyositis found many more T cells than B cells, suggesting a role for intramuscular cell-mediated immune mechanisms rather than humoral mechanisms. Microarray studies were performed on muscle biopsy
Miho Kimura et al.
International journal of hematology, 85(1), 41-48 (2007-01-31)
To clarify the clinicopathologic significance of a loss of CD19 expression in diffuse large B-cell lymphoma (DLBCL), we evaluated CD19 expression immunohistochemically in frozen sections from 227 patients who had received diagnoses of DLBCL according to the World Health Organization
N Masir et al.
Histopathology, 48(3), 239-246 (2006-01-25)
To investigate whether an antibody against an intracellular epitope can detect CD19 in routine biopsy specimens and thus to document in detail its expression in human lymphomas. A polyclonal antibody to the C terminus of CD19 was used to immunostain

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica